New and controversial therapies for chronic obstructive pulmonary disease

Proceedings of the American Thoracic Society

Volumn 6, Issue 6, 2009, Pages 553-554

  Bourbeau, Jean ^a   Johnson, Malcolm ^b  

^a MCGILL UNIVERSITY   (Canada)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antiinflammatory effect; COPD; Drug therapy; Self management

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DEXAMETHASONE; GW 856553; HISTONE DEACETYLASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; MUSCARINIC RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PH 797804; PHOSPHATIDYLINOSITOL 3 KINASE;

BEHAVIOR CHANGE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DISEASE COURSE; DRUG POTENTIATION; ENZYME ACTIVATION; HOSPITAL ADMISSION; HUMAN; PRACTICE GUIDELINE; PROTEIN EXPRESSION; SELF CARE; SELF CONCEPT; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHODILATOR AGENTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SELF CARE; STEROIDS;

EID: 70349083749     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200906-039DS     Document Type: Conference Paper

References (12)

1. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26:214-222. (Pubitemid 41079064)
2. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK; SCO30005 Study Group. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-743.
3. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomized controlled trial. Thorax 2007. (Pubitemid 350084490)
4. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-1976. (Pubitemid 40638367)
5. Bhavsar PK, Khorasani NJM, et al. Improvement in corticosteroid sensitivity in PBMCs from patients with COPD by p38 MAPK inhibition. Am J Respir Crit Care Med 2009;179:A6187.
6. Marwick JA, Caramori G, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham PA, Papi A. Inhibition of PI3Kd restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 2009;179:542-548.
7. Bourbeau J, Nault D, Dang-Tan T. Self-management and behaviour modification in COPD. Patient Educ Couns 2004;52:271-277.
8. Bourbeau J, van der Palen J. Promoting effective self-management programmes to improve COPD. Eur Respir J 2009;33:461-463.
9. Effing T, Monninkhof E, van der Valk, van der Palen J, van Herwaarden C, Partidge M, Walters E, Zielhuis G. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD002990. (Pubitemid 351805368)
10. Turnock AC, Walters EH, Walters JA, Wood-Baker R. Action plans for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;4:CD005074.
11. Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge MR. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax 2008;63:194-200.
12. Sedeno MF, Nault D, Hamd DH, Borubeau J. A self-management education program including an action plan for acute COPD exacerbations. COPD 2009 (In press)